Skip to main content

Table 3 Univariate analysis of patient and treatment related factors in relation to overall survival

From: Radiation dose ≥54 Gy and CA 19–9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation

  

Median OS (months)

p value

Age

<60

8.8

 
 

≥60

7.0

0.778

T classification

T3

4.9

 
 

T4

8.9

0.120

N classification

N0

8.8

 
 

N1

8.9

0.543

Exploratory laparotomy

No

8.9

 
 

Yes

8.5

0.550

Neoadjuvant chemotherapy

No

8.8

 
 

Yes

6.6

0.814

RT dose delivered

<54 Gy

6.8

 
 

≥54 Gy

11.3

0.089

RT modality

IMRT

8.8

 
 

3D

8.5

0.275

Protocol

On

8.5

 
 

Off

9.0

0.123

TNFerade

No

8.8

 
 

Yes

11.3

0.996

CA 19–9 pre-CRT

<90 U/mL

8.8

 
 

≥90 U/mL

8.8

0.626

CA 19–9 post-CRT minimum

<90 U/mL

12.3

 
 

≥90 U/mL

8.8

0.012

  1. (3D = three dimensional conformal radiotherapy; CA 19–9 = carbohydrate antigen 19–9; CRT = chemoradiation; IMRT = intensity modulated radiotherapy; RT = radiotherapy).